Agenda   Click here to download a PDF version of the Agenda for this meeting.   *This file is in PDF format, which requires the free Adobe Acrobat Reader for viewing. Attention visually impaired visitors: To use common screen reading programs with PDF documents, please visit http://access.adobe.com. This site provides free tools that convert PDF documents to simple HTML or ASCII text.   Aims of the meeting: To assess current understanding of hepatitis B virus (HBV), the disease that it causes, and its optimal management; and to make recommendations for directions for future research, both basic and clinical. Topics will include HBV replication and mode of inducing chronicity, the immunology of hepatitis B, the virus-host interactions, the natural history of chronic infection, and up-to-date results of trials of antiviral therapies, including peginterferon, la.m.ivudine, adefovir dipivoxil, tenofovir, entecavir, and LdT alone and in combination. Histological, clinical, and virological endpoints of therapy and the needs for future research will be discussed. The meeting will be sponsored by the Liver Disease Research Branch of the Division of Digestive Diseases and Nutrition of NIDDK in collaboration with the A.m.erican Association for the Study of Liver Disease (AASLD), the A.m.erican Liver Foundation, the Hepatitis B Foundation and Hepatitis Foundation International. A summary of the meeting and these recommendations will be submitted for publication. In preparation for the meeting, the following documents will be prepared: 1. Standardized definitions of response and endpoints of therapy. 2. Guidelines for the format of presentation of results of clinical trials.   Thursday, April 6, 2006 8:30 a.m. Welcome and Aims Jay Hoofnagle             Session 1: Virology and Pathogenesis Moderators: Ed Doo and Jack Wands       8:40 a.m. HBV Replication (32 KB) William Mason 9:00 a.m. HBV Pathogenesis (32 KB) Stefan Wieland 9:20 a.m. HBV Immunology (28 KB) Barbara Rehermann 9:40 a.m. Discussion (30 minutes)         10:10 a.m. Break (30 minutes)               Session 2: Natural History Moderators: Leonard Seeff and Patrick Marcellin       10:40 a.m. Natural History in Asian Cohorts (24 KB) Jia-Horng Kao 11:00 a.m. Natural History in European Countries (36 KB) Solko Schalm 11:20 a.m. Liver Histology (24 KB) Zack Goodman 11:40 a.m. Fibrosis Markers (36 KB) Robert Fontana 12:00 noon Discussion (30 minutes)         12:30 p.m. Lunch (60 minutes)               Session 3: Therapy and Mechanisms Moderators: Jenny Heathcote and Ray Chung       1:30 p.m. Overview of Therapy (28 KB) Anna Lok 1:50 p.m. Tests for HBV (24 KB) Jean-Michel Pawlotsky 2:10 p.m. The Woodchuck Model of HBV (12 KB) Brent Korba 2:30 p.m. Mechanisms of Action of Antivirals (16 KB) Loren Tyrrell 2:50 p.m. Discussion (20 minutes)         3:10 p.m. Break (20 minutes)               Session 4: Monotherapy for Hepatitis B Moderators: Jay Hoofnagle and Norah Terrault       3:30 p.m. Peginterferon (20 KB) Alfredo Alberti 3:50 p.m. La.m.ivudine (52 KB) Marc Ghany 4:10 p.m. LdT (84 KB) Adrian Di Bisceglie 4:30 p.m. Adefovir dipivoxil (20 KB) Stephanos Hadziyannis 4:50 p.m. Tenofovir and FTC (20 KB) Marion Peters 5:10 p.m. Entecavir (36 KB) Eugene Schiff 5:30 p.m. Discussion (30 minutes)         6:00 p.m. Poster Review Reception (Natcher Auditorium Lobby)                         Friday, April 7, 2006   Session 5: Viral Issues in Therapy Moderators: Anna Lok and Daryl Lau       8:30 a.m. Viral Kinetics in HBV (28 KB) Avidan Neumann 8:50 a.m. Viral Resistance in HBV (64 KB) Stephen Locarnini 9:10 a.m. Clinical Issues in Viral Resistance (44 K) Fabien Zoulim 9:30 a.m. HBV DNA, Genotypes and Responses (24 KB) Harry Janssen 9:50 a.m. Discussion (30 minutes)         10:20 a.m. Break (30 minutes)               Session 6: Combination Therapy of HBV Moderators: Jake Liang and John Vierling       10:50 a.m. Overview of Combination Therapy (104 KB) Jenny Heathcote 11:10 a.m. Nucleoside Combinations (36 KB) Robert Perrillo 11:30 a.m. Peginterferon and Nucleosides (20 KB) Patrick Marcellin 11:50 a.m. Discussion (40 minutes)         12:30 p.m. Lunch (60 minutes)               Session 7: Special Populations and Special Issues Moderators: Marc Ghany and Eugene Schiff       1:30 p.m. Children With HBV (72 KB) Jean Molleston 1:50 p.m. Decompensated Liver Disease (28 KB) Norah Terrault 2:10 p.m. HBV/HIV Coinfection (24 KB) Chloe Thio 2:30 p.m. Chemotherapy and Immune Suppression (12 KB) George Lau 2:50 p.m. Discussion (25 minutes)         3:15 p.m. Break (30 minutes)               Session 8: Safety and Cost Issues Moderators: Russ Fleischer and Robert Fontana       3:45 p.m. Prevention of Maternal-Infant Spread (12 KB) Tony H. H. Chen 4:05 p.m. Safety of Therapy During Pregnancy (24 KB) Brenda Ross 4:25 p.m. Costs of Therapy (16 KB) John Wong 4:45 p.m. Complications of Therapy (64 KB) John Vierling 5:05 p.m. Discussion (25 minutes)         5:30 p.m. Adjournment               Saturday, April 8, 2006     Session 9: Special Situations and Future Therapy Moderators: Robert Perrillo and Tim Block       8:30 a.m. Acute Hepatitis B (32 KB) Jay Hoofnagle 8:50 a.m. Prevention of HCC (24 KB) Yun Fan Liaw 9:10 a.m. Future Therapies (20 KB) T Jake Liang 9:30 a.m. Design Issues in Future Studies (12 KB) Russ Fleischer 9:50 a.m. Discussion (30 minutes)         10:20 a.m. Break (30 minutes)               Session 10: Conclusions and Recommendations   10:50 a.m. Discussion: Indications for Therapy of Chronic Hepatitis B:   Moderators: Jay Hoofnagle, Anna Lok, and John Vierling       12:00 noon Adjournment                     Back to Top

Return to NIDDK homepage. This page last updated: 4/25/2006